{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:02:13Z","timestamp":1793062933288,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.euf.2024.08.008","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T20:42:52Z","timestamp":1725396172000},"page":"62-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Patient-derived Organoids in Bladder Cancer: Opportunities and Challenges"],"prefix":"10.1016","volume":"11","author":[{"given":"Martina","family":"Radi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Egger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Kruithof-de Julio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2024.08.008_b0005","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00345-009-0383-3","article-title":"The present and future burden of urinary bladder cancer in the world","volume":"27","author":"Ploeg","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2024.08.008_b0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.08.008_b0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.08.008_b0020","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.08.008_b0025","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.euf.2024.08.008_b0030","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.08.008_b0035","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1097\/PAS.0000000000001371","article-title":"Multicenter validation of histopathologic tumor regression grade after neoadjuvant chemotherapy in muscle-invasive bladder carcinoma","volume":"43","author":"Voskuilen","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.euf.2024.08.008_b0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eururo.2008.07.018","article-title":"Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience","volume":"55","author":"Donat","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.08.008_b0045","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.08.008_b0050","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.08.008_b0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.08.008_b0060","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2024.08.008_b0065","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2024.08.008_b0070","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2024.08.008_b0075","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2024.08.008_b0080","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","article-title":"Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes","volume":"81","author":"Sj\u00f6dahl","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.08.008_b0085","doi-asserted-by":"crossref","DOI":"10.1126\/science.1247125","article-title":"Organogenesis in a dish: modeling development and disease using organoid technologies","volume":"345","author":"Lancaster","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.euf.2024.08.008_b0090","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1073\/pnas.1803595116","article-title":"Mouse and human urothelial cancer organoids: a tool for bladder cancer research","volume":"116","author":"Mullenders","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.euf.2024.08.008_b0095","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor evolution and drug response in patient-derived organoid models of bladder cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.euf.2024.08.008_b0100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A living biobank of breast cancer organoids captures disease heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.euf.2024.08.008_b0105","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.stem.2016.04.003","article-title":"A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis","volume":"18","author":"Fujii","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.euf.2024.08.008_b0110","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41467-020-15155-6","article-title":"An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity","volume":"11","author":"Calandrini","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.euf.2024.08.008_b0115","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/nm.4438","article-title":"Human primary liver cancer-derived organoid cultures for disease modeling and drug screening","volume":"23","author":"Broutier","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.euf.2024.08.008_b0120","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","article-title":"An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity","volume":"25","author":"Kopper","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.euf.2024.08.008_b0125","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s12885-018-4238-4","article-title":"Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models","volume":"18","author":"Tsai","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euf.2024.08.008_b0130","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nprot.2016.006","article-title":"Organoid culture systems for prostate epithelial and cancer tissue","volume":"11","author":"Drost","year":"2016","journal-title":"Nat Protoc"},{"key":"10.1016\/j.euf.2024.08.008_b0135","doi-asserted-by":"crossref","first-page":"11060","DOI":"10.18632\/oncotarget.24308","article-title":"Three-dimensional organoid culture reveals involvement of Wnt\/\u03b2-catenin pathway in proliferation of bladder cancer cells","volume":"9","author":"Yoshida","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2024.08.008_b0140","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41698-023-00466-w","article-title":"Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer","volume":"7","author":"Garioni","year":"2023","journal-title":"Npj Precis Oncol"},{"key":"10.1016\/j.euf.2024.08.008_b0145","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/s42003-021-02910-8","article-title":"Towards organoid culture without Matrigel","volume":"4","author":"Kozlowski","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.euf.2024.08.008_b0150","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41578-020-0199-8","article-title":"Synthetic alternatives to Matrigel","volume":"5","author":"Aisenbrey","year":"2020","journal-title":"Nat Rev Mater"},{"key":"10.1016\/j.euf.2024.08.008_b0155","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41467-023-37696-2","article-title":"Bladder cancer organoids as a functional system to model different disease stages and therapy response","volume":"14","author":"Minoli","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.euf.2024.08.008_b0160","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12894-023-01262-1","article-title":"Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial","volume":"23","author":"Seiler","year":"2023","journal-title":"BMC Urol"},{"key":"10.1016\/j.euf.2024.08.008_b0165","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.22.00470","article-title":"DaBlaCa-13 Study: Oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: primary outcome of a randomized controlled trial","volume":"41","author":"Lindgren","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2024.08.008_b0170","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41416-023-02494-6","article-title":"Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation","volume":"130","author":"Viergever","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2024.08.008_b0175","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2024.08.008_b0180","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","article-title":"Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer","volume":"26","author":"Yao","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.euf.2024.08.008_b0185","article-title":"Immune checkpoint inhibitors as a treatment option for bladder cancer: current evidence","volume":"15","author":"Okobi","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.euf.2024.08.008_b0190","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/0008-5472.CAN-20-4026","article-title":"Patient-derived organoids for precision cancer immunotherapy","volume":"81","author":"Gr\u00f6nholm","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.euf.2024.08.008_b0195","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1158\/2159-8290.CD-17-0833","article-title":"Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids","volume":"8","author":"Jenkins","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euf.2024.08.008_b0200","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.cell.2018.11.021","article-title":"Organoid modeling of the tumor immune microenvironment","volume":"175","author":"Neal","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.euf.2024.08.008_b0205","article-title":"Patient-derived Immunocompetent tumor organoids: a platform for chemotherapy evaluation in the context of T-cell recognition","volume":"63","author":"Zhao","year":"2024","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.euf.2024.08.008_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00166","article-title":"Modeling cell communication in cancer with organoids: making the complex simple","volume":"8","author":"Fiorini","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.euf.2024.08.008_b0215","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.euf.2024.08.008_b0220","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/CU9.0000000000000219","article-title":"Patient-derived bladder cancer organoid model to predict sensitivity and feasibility of tailored precision therapy","volume":"17","author":"Jiang","year":"2023","journal-title":"Curr Urol"},{"key":"10.1016\/j.euf.2024.08.008_b0225","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1248","article-title":"Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro","volume":"10","author":"Yu","year":"2021","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.euf.2024.08.008_b0230","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.3390\/cells12172188","article-title":"A protocol for organoids from the urine of bladder cancer patients","volume":"12","author":"Walz","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.euf.2024.08.008_b0235","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/diagnostics13061032","article-title":"Circulating tumor cells predict response of neoadjuvant chemotherapy in patients with bladder cancer: a preliminary study","volume":"13","author":"Jhuo","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.euf.2024.08.008_b0240","doi-asserted-by":"crossref","first-page":"606.e9","DOI":"10.1016\/j.urolonc.2017.05.021","article-title":"Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: association with tumor stage, lymph node metastases, FDG-PET findings, and survival","volume":"35","author":"Abrahamsson","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2024.08.008_b0245","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ijc.30445","article-title":"A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy","volume":"140","author":"Soave","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euf.2024.08.008_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsamd.2019.01.006","article-title":"Novel approaches in cancer management with circulating tumor cell clusters","volume":"4","author":"Rostami","year":"2019","journal-title":"J Sci Adv Mater Devices"},{"key":"10.1016\/j.euf.2024.08.008_b0255","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/bjc.2011.545","article-title":"A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker","volume":"106","author":"Khoja","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euf.2024.08.008_b0260","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1373\/clinchem.2011.175570","article-title":"Circulating epithelial cells in patients with benign colon diseases","volume":"58","author":"Pantel","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.euf.2024.08.008_b0265","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nprot.2017.125","article-title":"Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device","volume":"13","author":"Khoo","year":"2018","journal-title":"Nat Protoc"},{"key":"10.1016\/j.euf.2024.08.008_b0270","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.3390\/cancers12102784","article-title":"Efficient propagation of circulating tumor cells: a first step for probing tumor metastasis","volume":"12","author":"Xiao","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euf.2024.08.008_b0275","doi-asserted-by":"crossref","first-page":"12383","DOI":"10.18632\/oncotarget.2592","article-title":"Expansion of CTCs from early stage lung cancer patients using a microfluidic co-culture model","volume":"5","author":"Zhang","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2024.08.008_b0280","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad054","article-title":"m6A epitranscriptome analysis reveals differentially methylated transcripts that drive early chemoresistance in bladder cancer","volume":"5","author":"Hodara","year":"2023","journal-title":"NAR Cancer"},{"key":"10.1016\/j.euf.2024.08.008_b0285","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202302377","article-title":"A HER2-targeted antibody-drug conjugate, RC48-ADC, exerted promising antitumor efficacy and safety with intravesical instillation in preclinical models of bladder cancer","volume":"10","author":"Hong","year":"2023","journal-title":"Adv Sci"},{"key":"10.1016\/j.euf.2024.08.008_b0290","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41419-023-05938-2","article-title":"UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to promote the lymphatic metastasis of bladder cancer","volume":"14","author":"Xiao","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.euf.2024.08.008_b0295","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.omto.2022.01.009","article-title":"Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer","volume":"24","author":"Rangsitratkul","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.euf.2024.08.008_b0300","doi-asserted-by":"crossref","first-page":"12277","DOI":"10.1038\/s41598-017-12543-9","article-title":"Microchamber cultures of bladder cancer: a platform for characterizing drug responsiveness and resistance in PDX and primary cancer cells","volume":"7","author":"Gheibi","year":"2017","journal-title":"Sci Rep"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924001652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924001652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T21:04:40Z","timestamp":1749762280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456924001652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2405456924001652"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2024.08.008","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-derived Organoids in Bladder Cancer: Opportunities and Challenges","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2024.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}